Short-Term Risk of Bleeding During Heparin Bridging at Initiation of Vitamin K Antagonist Therapy in More Than 90 000 Patients With Nonvalvular Atrial Fibrillation Managed in Outpatient Care.

Date publication

octobre 2016

Journal

Journal of the American Heart Association

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BOUDALI Lotfi

Tous les auteurs :
Bouillon K, Bertrand M, Boudali L, Ducimetière P, Dray-Spira R, Zureik M

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/27799233

Résumé

Several studies have recently examined the risks of bleeding and of ischemic stroke and systemic embolism associated with perioperative heparin bridging anticoagulation in patients with nonvalvular atrial fibrillation. However, few studies have investigated bridging risks during vitamin K antagonist initiation in outpatient settings.

Mots clés

anticoagulant, arterial thrombosis, bleeding, heparin bridging, nonvalvular atrial fibrillation, vitamin K antagonist

Référence

J Am Heart Assoc. 2016 10 31;5(11):